Next Article in Journal / Special Issue
Long-Term Dynamics of Three Dimensional Telomere Profiles in Circulating Tumor Cells in High-Risk Prostate Cancer Patients Undergoing Androgen-Deprivation and Radiation Therapy
Previous Article in Journal
Tailor-Made Detection of Individual Phosphorylated and Non-Phosphorylated EPIYA-Motifs of Helicobacter pylori Oncoprotein CagA
Previous Article in Special Issue
Analysis of AR/ARV7 Expression in Isolated Circulating Tumor Cells of Patients with Metastatic Castration-Resistant Prostate Cancer (SAKK 08/14 IMPROVE Trial)
Open AccessReview

Evolving Clinical Utility of Liquid Biopsy in Gastrointestinal Cancers

1
Department of Surgery, Rush University Medical Center, Chicago, IL 60612, USA
2
Division of Hematology/Oncology and Cell Therapy, Rush University Medical Center, Chicago, IL 60612, USA
3
Rush Precision Oncology Program, Rush University Medical Center, Chicago, IL 60612, USA
*
Author to whom correspondence should be addressed.
Cancers 2019, 11(8), 1164; https://doi.org/10.3390/cancers11081164
Received: 25 July 2019 / Revised: 30 July 2019 / Accepted: 6 August 2019 / Published: 13 August 2019
(This article belongs to the Special Issue Liquid Biopsy for Cancer)
  |  
PDF [963 KB, uploaded 19 August 2019]
  |     |  

Abstract

Room for improvement exists regarding recommendations for screening, staging, therapy selection, and frequency of surveillance of gastrointestinal cancers. Screening is costly and invasive, improved staging demands increased sensitivity and specificity to better guide therapy selection. Surveillance requires increased sensitivity for earlier detection and precise management of recurrences. Peripherally collected blood-based liquid biopsies enrich and analyze circulating tumor cells and/or somatic genomic material, including circulating tumor DNA along with various subclasses of RNA. Such assays have the potential to impact clinical practice at multiple stages of management in gastrointestinal cancers. This review summarizes current basic and clinical evidence for the utilization of liquid biopsy in cancers of the esophagus, pancreas, stomach, colon, and rectum. Technical aspects of various liquid biopsy methodologies and targets are reviewed and evidence supporting current commercially available assays is examined. Finally, current clinical applicability, potential future uses, and pitfalls of applying liquid biopsy to the screening, staging and therapeutic management of these diseases are discussed. View Full-Text
Keywords: gastrointestinal cancer; liquid biopsy; circulating tumor cell; circulating tumor DNA gastrointestinal cancer; liquid biopsy; circulating tumor cell; circulating tumor DNA
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Jacobson, R.A.; Munding, E.; Hayden, D.M.; Levy, M.; Kuzel, T.M.; Pappas, S.G.; Masood, A. Evolving Clinical Utility of Liquid Biopsy in Gastrointestinal Cancers. Cancers 2019, 11, 1164.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top